Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Although the main focus of immuno-oncology has been manipulating the adaptive immune system, harnessing both the innate and adaptive arms of the immune system might produce superior tumour reduction and elimination. Tumour-associated macrophages often have net pro-tumour effects, but their embedded location and their untapped potential provide impetus to discover strategies to turn them against tumours. Strategies that deplete (anti-CSF-1 antibodies and CSF-1R inhibition) or stimulate (agonistic anti-CD40 or inhibitory anti-CD47 antibodies) tumour-associated macrophages have had some success. We hypothesized that pharmacologic modulation of macrophage phenotype could produce an anti-tumour effect. We previously reported that a first-in-class selective class IIa histone deacetylase (HDAC) inhibitor, TMP195, influenced human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro. Here, we utilize a macrophage-dependent autochthonous mouse model of breast cancer to demonstrate that in vivo TMP195 treatment alters the tumour microenvironment and reduces tumour burden and pulmonary metastases by modulating macrophage phenotypes. TMP195 induces the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumours. Furthermore, combining TMP195 with chemotherapy regimens or T-cell checkpoint blockade in this model significantly enhances the durability of tumour reduction. These data introduce class IIa HDAC inhibition as a means to harness the anti-tumour potential of macrophages to enhance cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone deacetylase inhibitor, TMP195, polarizes TAMs toward an anti‐tumor phenotype and increases the efficacy of carboplatin, paclitaxel, and anti‐PD‐1 therapies [84].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
The Immunological Genome Project: networks of gene expression in immune cells
The Immunological Genome Project Consortium, Heng, T. S. P., Painter, M. W., Elpek, K., Lukacs-Kornek, V., Mauermann, N., Turley, S. J., Koller, D., Kim, F. S., Wagers, A. J., et al. (2008) · Nature Immunology · doi:10.1038/ni1008-1091 · Cited by 1,864
Self-citation
Research works printed but not linked: 2
- DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL & Coussens LM Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery 1, 54– 67, 10.1158/2159-8274.cd-10-0028 (2011). 22039576 PMC3203524 · DOI · Paper page
- Malhotra D, Fletcher AL, Astarita J, Lukacs-Kornek V, Tayalia P, Gonzalez SF, Elpek KG, Chang SK, Knoblich K, Hemler ME, Brenner MB, Carroll MC, Mooney DJ, Turley SJ & Immunological Genome Project C Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nature immunology 13, 499– 510, 10.1038/ni.2262 (2012). 22466668 PMC3366863 · DOI · Paper page
Cited by
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
“Additionally, TAMs mediate the efficacy of the anti-tumor and anti-metastatic effects of the histone deacetylase inhibitor TMP195, which reprograms TAMs to a highly phagocytic phenotype (Guerriero et al. 2017).”
BackgroundDiversity, Mechanisms, and Significance of Macrophage Plasticity
Locati, M., Curtale, G., & Mantovani, A. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012718 · Cited by 2,199
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Tumor microenvironment as a therapeutic target in cancer
Xiao, Y., & Yu, D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,957
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Rodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099
The Short Chain Fatty Acid Butyrate Imprints an Antimicrobial Program in Macrophages
Schulthess, J., Pandey, S., Capitani, M., Rue-Albrecht, K. C., Arnold, I., Franchini, F., Chomka, A., Ilott, N. E., Johnston, D. G. W., Pires, E., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.018 · Cited by 1,037
“We initially treated macrophages with TMP195, an inhibitor of HDAC class IIa (Davie, 2003) that has been used to activate tumor-associated macrophages (Guerriero et al., 2017) and with tubacin that targets HDAC class IIb.”
MethodTargeting tumor-associated macrophages in cancer
Pathria, P., Louis, T. L., & Varner, J. A. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.003 · Cited by 933
Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743
“Compensation was performed manually on BD FACSDiva using single color and isotype controls, in line with our previous work (43).”
MethodDeciphering breast cancer: from biology to the clinic
Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 730
Clinical relevance of tumour-associated macrophages
Pittet, M. J., Michielin, O., & Migliorini, D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00620-6 · Cited by 731
De-novo and acquired resistance to immune checkpoint targeting
Syn, N. L., Teng, M. W. L., Mok, T. S. K., & Soo, R. A. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30607-1 · Cited by 662
Targeting macrophages in cancer immunotherapy
Duan, Z., & Luo, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00506-6 · Cited by 625
Metabolic Regulation of Macrophage Polarization in Cancer
Mehla, K., & Singh, P. K. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.10.007 · Cited by 617
A timeline of tumour-associated macrophage biology
Cassetta, L., & Pollard, J. W. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00547-1 · Cited by 581
“Similarly, inhibition of macrophage-restricted class IIa histone deacetylases resulted in a switch from pro-tumoural to anti-tumoural TAMs and enhanced response to both immunotherapy and chemotherapy 227 .”
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 573
“However, tumors that transition into mesenchymal states by inflammatory cytokines or oncogenic signals exhibit an immuneTME that excludes T cells and supports suppressive TAMs and MDSCs. Chronic cytokine signals such as IFN can exacerbate immune suppression through various mechanisms, which can contrast with their typ…”
BackgroundInfluentialChen, D., Xie, J., Fiskesund, R., Dong, W., Liang, X., Lv, J., Jin, X., Liu, J., Mo, S., Zhang, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03225-9 · Cited by 489
Differentiation therapy revisited
de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462
Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
Qiu, S.-Q., Waaijer, S. J. H., Zwager, M. C., de Vries, E. G. E., van der Vegt, B., & Schröder, C. P. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.010 · Cited by 425
“This drug modulated TAMs into the M1-like phenotype, and decreased tumor burden in MMTV-PyMT mice, particularly when combined with paclitaxel [65].”
BackgroundWanderley, C. W., Colón, D. F., Luiz, J. P. M., Oliveira, F. F., Viacava, P. R., Leite, C. A., Pereira, J. A., Silva, C. M., Silva, C. R., Silva, R. L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3480 · Cited by 420
“More recently, it was demonstrated that the activation of macrophages by treatment with class IIa histone deacetylase inhibitor improves the efficacy of chemotherapy and checkpoint blockade in mice with breast tumors (35).”
BackgroundCellular backpacks for macrophage immunotherapy
Shields, C. W., Evans, M. A., Wang, L. L.-W., Baugh, N., Iyer, S., Wu, D., Zhao, Z., Pusuluri, A., Ukidve, A., Pan, D. C., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6579 · Cited by 414
Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers
Larionova, I., Tuguzbaeva, G., Ponomaryova, A., Stakheyeva, M., Cherdyntseva, N., Pavlov, V., Choinzonov, E., & Kzhyshkowska, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.566511 · Cited by 392
Harnessing tumor‐associated macrophages as aids for cancer immunotherapy
Li, X., Liu, R., Su, X., Pan, Y., Han, X., Shao, C., & Shi, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1102-3 · Cited by 364
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Li, G., Tian, Y., & Zhu, W.-G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576946 · Cited by 352
Qian, Y., Qiao, S., Dai, Y., Xu, G., Dai, B., Lu, L., Yu, X., Luo, Q., & Zhang, Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b05465 · Cited by 333
Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies
Kumari, N., & Choi, S. H. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02272-x · Cited by 315
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“Histone deacetylase inhibitor, TMP195, polarizes TAMs toward an anti-tumor phenotype and increases the efficacy of carboplatin, paclitaxel, and anti-PD-1 therapies [84].”
BackgroundCurrent Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
Anfray, C., Ummarino, A., Andón, F. T., & Allavena, P. (2019) · Cells · doi:10.3390/cells9010046 · Cited by 304
Therapeutic targeting of tumour myeloid cells
Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D., & Morton, J. P. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00546-2 · Cited by 305
Tailoring Nanomaterials for Targeting Tumor‐Associated Macrophages
Ovais, M., Guo, M., & Chen, C. (2019) · Advanced Materials · doi:10.1002/adma.201808303 · Cited by 298
Liu, M., O’Connor, R. S., Trefely, S., Graham, K., Snyder, N. W., & Beatty, G. L. (2019) · Nature Immunology · doi:10.1038/s41590-018-0292-y · Cited by 294
Macrophages: The Road Less Traveled, Changing Anticancer Therapy
Guerriero, J. L. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.03.006 · Cited by 293
“TMP195-activated macrophages became highly phagocytic and displayed an IFNγ gene signature [75].”
BackgroundSelf-citationAcquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.017 · Cited by 292
Dong, L., Chen, C., Zhang, Y., Guo, P., Wang, Z., Li, J., Liu, Y., Liu, J., Chang, R., Li, Y., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.016 · Cited by 278
Mehta, A. K., Cheney, E. M., Hartl, C. A., Pantelidou, C., Oliwa, M., Castrillon, J. A., Lin, J.-R., Hurst, K. E., de Oliveira Taveira, M., Johnson, N. T., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00148-7 · Cited by 275
Self-citationXie, Z., Peng, M., Lu, R., Meng, X., Liang, W., Li, Z., Qiu, M., Zhang, B., Nie, G., Xie, N., et al. (2020) · Light: Science & Applications · doi:10.1038/s41377-020-00388-3 · Cited by 265
Activating a collaborative innate-adaptive immune response to control metastasis
Sun, L., Kees, T., Almeida, A. S., Liu, B., He, X.-Y., Ng, D., Han, X., Spector, D. L., McNeish, I. A., Gimotty, P., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.005 · Cited by 267
Cancer Stemness Meets Immunity: From Mechanism to Therapy
Chen, P., Hsu, W.-H., Han, J., Xia, Y., & DePinho, R. A. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108597 · Cited by 252
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2018.07.001 · Cited by 245
Self-citationToll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages
Müller, E., Christopoulos, P. F., Halder, S., Lunde, A., Beraki, K., Speth, M., Øynebråten, I., & Corthay, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01383 · Cited by 239
“Cancer Immunol Immuno ther (2012) 61(10):1683–97.”
Role of HDACs in normal and malignant hematopoiesis
Wang, P., Wang, Z., & Liu, J. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1127-7 · Cited by 235
He, W., Kapate, N., Shields, C. W., & Mitragotri, S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.12.001 · Cited by 236
Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer
Mehta, A. K., Kadel, S., Townsend, M. G., Oliwa, M., & Guerriero, J. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643771 · Cited by 231
“CD40 agonists (193), PI3Kγ inhibitors (194), CD47 inhibitors (195), and a class IIa HDAC inhibitor (179) have all been shown to reduce primary and metastatic murine breast tumors (179) and have emerged as novel modalities to convert TAMs to anti-tumor macrophages.”
BackgroundSelf-citationGe, Z., & Ding, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.590941 · Cited by 222
Myeloid cell-targeted therapies for solid tumours
Goswami, S., Anandhan, S., Raychaudhuri, D., & Sharma, P. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00737-w · Cited by 220
Di Mitri, D., Mirenda, M., Vasilevska, J., Calcinotto, A., Delaleu, N., Revandkar, A., Gil, V., Boysen, G., Losa, M., Mosole, S., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.068 · Cited by 221
“, 2018) and are known to influence tumor growth by controlling adaptive immunity, angiogenesis, tumor cell proliferation, and metastasis formation, thus playing a fundamental role in cancer initiation, progression, and resistance to treatment (Baer et al., 2016; Bingle et al., 2002; Guerriero et al., 2017; Kaneda et a…”
InfluentialMacrophage targeting in cancer
Lopez‐Yrigoyen, M., Cassetta, L., & Pollard, J. W. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14377 · Cited by 221
Tumor-associated myeloid cells: diversity and therapeutic targeting
Mantovani, A., Marchesi, F., Jaillon, S., Garlanda, C., & Allavena, P. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00613-4 · Cited by 219
Kureshi, C. T., & Dougan, S. K. (2025) · Cancer Cell · doi:10.1016/j.ccell.2024.11.011 · Cited by 213
Innate Immunity and Cancer Pathophysiology
Maiorino, L., Daßler-Plenker, J., Sun, L., & Egeblad, M. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-032221-115501 · Cited by 215
Cassetta, L., & Kitamura, T. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00038 · Cited by 200
“In the mammary tumors developed in PyMT transgenic mice, a selective class IIa HDAC inhibitor (TMP195) switches dominant macrophage populations in the tumor from TAM to highly phagocytic macrophages, which suppresses tumor growth (Guerriero et al., 2017).”
BackgroundLi, C., Zhang, Y., Dong, X., Zhang, L., Liu, M., Li, B., Zhang, M., Feng, J., & Zhang, X. (2019) · Advanced Materials · doi:10.1002/adma.201807211 · Cited by 201
Garrido-Martin, E. M., Mellows, T. W. P., Clarke, J., Ganesan, A.-P., Wood, O., Cazaly, A., Seumois, G., Chee, S. J., Alzetani, A., King, E. V., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000778 · Cited by 196
Emerging Targeted Therapies for HER2-Positive Breast Cancer
Mercogliano, M. F., Bruni, S., Mauro, F. L., & Schillaci, R. (2023) · Cancers · doi:10.3390/cancers15071987 · Cited by 194
“Among those strategies, it is worth mentioning the inhibition of the CCL2-CCL2R axis [393–396], enhancing the activation of macrophages and dendritic cells through TLR and CD40 agonists [397], inhibiting the immunosuppressive pathway of CD47-SIRPα [397], and promoting reprogramming to the M1-like subtype by inhibiting…”
BackgroundSedighzadeh, S. S., Khoshbin, A. P., Razi, S., Keshavarz-Fathi, M., & Rezaei, N. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1241 · Cited by 189
“A selective class IIa HDAC inhibitor evokes anti-tumor macrophage phenotypes that assist T cell responses and augments responses to chemotherapy and immune checkpoint inhibition, particularly in mammary tumor models (267).”
BackgroundTumor-Associated Macrophage Status in Cancer Treatment
Malfitano, A. M., Pisanti, S., Napolitano, F., Di Somma, S., Martinelli, R., & Portella, G. (2020) · Cancers · doi:10.3390/cancers12071987 · Cited by 184
“The histone deacetylase inhibitor TMP195 is able to address TAMs toward M1 profile, modifying their epigenetic signature and inducing their accumulation and phagocytic activity in the microenvironment of breast tumors [56].”
BackgroundRoles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies
Zhu, S., Yi, M., Wu, Y., Dong, B., & Wu, K. (2021) · Experimental Hematology & Oncology · doi:10.1186/s40164-021-00252-z · Cited by 178
“Carboplatin, Paclitaxel, and antiPD-1 drugs [186].”
Li, X., Su, X., Liu, R., Pan, Y., Fang, J., Cao, L., Feng, C., Shang, Q., Chen, Y., Shao, C., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01636-x · Cited by 160
Macrophage targeting: opening new possibilities for cancer immunotherapy
Cassetta, L., & Kitamura, T. (2018) · Immunology · doi:10.1111/imm.12976 · Cited by 166
“In this model, administration of TMP195 combined with anti-PD1 antibody significantly suppresses tumour development whereas a single treatment with TMP195 or anti-PD1 antibody shows modest suppression in the tumour burden.(47) Therefore, targeting master regulators of macrophage differentiation (e.”
MethodInhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization
Tan, B., Shi, X., Zhang, J., Qin, J., Zhang, N., Ren, H., Qian, M., Siwko, S., Carmon, K., Liu, Q., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0152 · Cited by 165
Re-Education of Macrophages as a Therapeutic Strategy in Cancer
Kowal, J., Kornete, M., & Joyce, J. A. (2019) · Immunotherapy · doi:10.2217/imt-2018-0156 · Cited by 161
Castaño, Z., San Juan, B. P., Spiegel, A., Pant, A., DeCristo, M. J., Laszewski, T., Ubellacker, J. M., Janssen, S. R., Dongre, A., Reinhardt, F., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0173-5 · Cited by 162
Targeting tumor-associated macrophages as an antitumor strategy
Cheng, N., Bai, X., Shu, Y., Ahmad, O., & Shen, P. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114354 · Cited by 161
Wang, Y.-C., Wang, X., Yu, J., Ma, F., Li, Z., Zhou, Y., Zeng, S., Ma, X., Li, Y.-R., Neal, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23164-2 · Cited by 157
Modulating inflammation for cancer therapy
Ritter, B., & Greten, F. R. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181739 · Cited by 159
Immune suppression and reversal of the suppressive tumor microenvironment
Shimizu, K., Iyoda, T., Okada, M., Yamasaki, S., & Fujii, S.-I. (2018) · International Immunology · doi:10.1093/intimm/dxy042 · Cited by 157
Nair, V. S., Salhat, H. E., Taha, R. Z., John, A., Ali, B. R., & Elkord, E. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0512-1 · Cited by 166
“Some recent reports showed that in breast cancer models, HDAC inhibition together with immune checkpoint blockades can reduce tumor growth and metastasis [58, 59].”
BackgroundZheng, Y., Han, Y., Sun, Q., & Li, Z. (2022) · Exploration · doi:10.1002/exp.20210166 · Cited by 169
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
Awad, R. M., De Vlaeminck, Y., Maebe, J., Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01977 · Cited by 151
“Bromodomain and extra-terminalmotif proteins (225) or histone deacetylase inhibitors (HDACi) (226–228), which interfere with chromatin remodeling, skew toward a TAM1 phenotype and were shown to mediate tumor regression in response to immune checkpoint therapy in a model in which monotherapy with anti-PD1 antibodies fa…”
BackgroundPrograms, origins and immunomodulatory functions of myeloid cells in glioma
Miller, T. E., Farran, C. A. E., Couturier, C., Chen, Z., D’Antonio, J. P., Verga, J. A., Villanueva, M. A., Castro, L. N. G., Tong, Y. E., Al-Saadi, T. D., et al. (2025) · Nature · doi:10.1038/s41586-025-08633-8 · Cited by 198
Self-citationMacrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention
Zhou, X., Liu, X., & Huang, L. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202006220 · Cited by 147
Clinical landscape of macrophage-reprogramming cancer immunotherapies
Rannikko, J. H., & Hollmén, M. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02715-6 · Cited by 183
“More recently, class IIa HDACs have been recognised as putative targets for inducing immunostimulation and phagocytosis in TAMs [175]; however, the complex functions of HDACs in immune cells warrant further studies [176].”
Briere, D. M., Sudhakar, N., Woods, D. M., Hallin, J. F., Engstrom, L. D., Aranda, R., Chiang, H., Sodré, A. L., Olson, P., Weber, J. S., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2091-y · Cited by 158
Yousefi, M., Nosrati, R., Salmaninejad, A., Dehghani, S., Shahryari, A., & Saberi, A. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0376-6 · Cited by 157
Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy
Zhang, S., Song, X., Yang, L., Ye, L., Zhou, Q., & Yang, W.-B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105111 · Cited by 148
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Wang, Y., Johnson, K. C. C., Gatti-Mays, M. E., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01335-y · Cited by 138
“Despite differential origins, TAMs are programmed by the surrounding environment to primarily suppress anti-tumor immunity, while the anti-tumor functions of TAMs in response to certain treatments, such as low-dose irradiation and histone deacetylase (HDAC) inhibitors, have also been described [30, 31].”
BackgroundIntegrating Nanotechnology into Cancer Care
Grodzinski, P. A., Kircher, M. F., Goldberg, M. S., & Gabizón, A. (2019) · ACS Nano · doi:10.1021/acsnano.9b04266 · Cited by 147
Tumor-Associated Macrophages: A Potential Target for Cancer Therapy
Tan, Y., Wang, M., Zhang, Y., Ge, S., Zhong, F., Xia, G., & Sun, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.693517 · Cited by 164
“Moreover, research has shown that TMP195, an antagonist of HDAC, reduced tumor growth and metastasis by modulating TAMs into a tumoricidal phenotype; furthermore, TMP195 enhanced the antitumor effect of PD-1 treatment and chemotherapy (150).”
BackgroundMechanisms of Resistance to Immune Checkpoint Blockade
Liu, D., Jenkins, R. W., & Sullivan, R. J. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0389-y · Cited by 130
Transcriptional, Epigenetic and Metabolic Programming of Tumor-Associated Macrophages
Larionova, I., Kazakova, E., Patysheva, M. R., & Kzhyshkowska, J. G. (2020) · Cancers · doi:10.3390/cancers12061411 · Cited by 138
“More recently, a class IIa HDAC inhibitor, TMP195, was found to reduce the tumor burden and metastasis by modulating TAM phenotypes to the antitumor, highly phagocytic cells in tumor-bearing MMTV-PyMT mice [203].”
BackgroundThe Remarkable Plasticity of Macrophages: A Chance to Fight Cancer
Bercovici, N., Guérin, M. V., Trautmann, A., & Donnadieu, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01563 · Cited by 122
“A specific Class IIa HDAC inhibitor, which appears to have no effect on T cells, is able to induce an inflammatory state by promoting the infiltration of phagocytic and immunostimulatory CD40 TAM, resulting in an antitumoral action (49).”
BackgroundYue, Y., Li, F., Li, Y., Wang, Y., Guo, X., Cheng, Z., Li, N., Ma, X., Nie, G., & Zhao, X. (2021) · ACS Nano · doi:10.1021/acsnano.1c05618 · Cited by 129
Tuning the Tumor Myeloid Microenvironment to Fight Cancer
Jahchan, N. S., Mujal, A. M., Pollack, J. L., Binnewies, M., Sriram, V., Reyno, L., & Krummel, M. F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01611 · Cited by 120
Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation
Li, T., Mao, C., Wang, X., Shi, Y., & Tao, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01733-5 · Cited by 120
miR-148a-3p Mediates Notch Signaling to Promote the Differentiation and M1 Activation of Macrophages
Huang, F., Zhao, J., Wang, L., Gao, C.-C., Liang, S.-Q., An, D., Bai, J., Chen, Y., Han, H., & Qin, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01327 · Cited by 123
“showed that the class IIa histone deacetylase inhibitor, TMP195, can harness the antitumor potential of macrophages to enhance cancer therapy (50).”
BackgroundImmune Escape during Breast Tumor Progression
del Alcazar, C. R. G., Alečković, M., & Polyák, K. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0786 · Cited by 127
“For example, inhibition of class IIA HDACs in luminal B breast cancer increased the efficacy and durability of immune checkpoint inhibitor and chemotherapy (54), while neutralization of the macrophage receptor with collagenous structure (MARCO) on a subset of inflammatory TAMs inhibited tumor metastasis (55).”
BackgroundJézéquel, P., Kerdraon, O., Hondermarck, H., Guérin‐Charbonnel, C., Lasla, H., Gouraud, W., Canon, J.-L. R., Gombos, A., Dalenc, F., Delaloge, S., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1148-6 · Cited by 134
Karagiannis, G. S., Condeelis, J. S., & Oktay, M. H. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1147 · Cited by 119
Targeting Innate Immunity in Cancer Therapy
Rameshbabu, S., Labadie, B. W., Argulian, A., & Patnaik, A. (2021) · Vaccines · doi:10.3390/vaccines9020138 · Cited by 129
“Class IIa histone deacetylase inhibitor, TMP195, demonstrated tumor reduction in breast cancer murine models by increasing the abundance of M1 macrophages [216].”
BackgroundMüller, E., Speth, M., Christopoulos, P. F., Lunde, A., Avdagic, A., Øynebråten, I., & Corthay, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02520 · Cited by 115
“Several interventions targeting macrophages have shown promising results inmousemodels for cancer, including a histone deacetylase inhibitor (10), agonistic anti-CD40 antibodies (9, 11), TGF-β inhibition in combination with toll-like receptor 7 (TLR7) ligation (12), and attenuated Listeria monocytogenes (13).”
BackgroundInsights into the Link Between Obesity and Cancer
Ackerman, S. E., Blackburn, O. A., Marchildon, F., & Cohen, P. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0263-x · Cited by 132
Targeting tumor‑associated macrophages in the tumor microenvironment (Review)
Zhou, K., Cheng, T., Zhan, J., Peng, X., Zhang, Y., Wen, J., Chen, X., & Ying, M. (2020) · Oncology Letters · doi:10.3892/ol.2020.12097 · Cited by 114
“PD‐1 antibody to reduce tumor burden and metastasis in an autochthonous mouse model of breast cancer (89).”
BackgroundPI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment
Collins, N. B., Abosy, R. A., Miller, B. C., Bi, K., Zhao, Q., Quigley, M. M., Ishizuka, J. J., Yates, K. B., Pope, H. W., Manguso, R. T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003402 · Cited by 135
Peng, H., Chen, B., Huang, W., Tang, Y., Jiang, Y., Zhang, W., & Huang, Y. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03756 · Cited by 113
Xiao, W., Liu, L., Li, X., Wang, Y., Guo, X., Zhao, J., & Zhou, S. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.09.021 · Cited by 117
Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic Plaque Vulnerability
Asare, Y., Campbell-James, T. A., Bokov, Y., Yu, L. L., Prestel, M., Bounkari, O. E., Roth, S., Megens, R. T. A., Straub, T., Thomas, K., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.316743 · Cited by 123
METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer
García-Vílchez, R., Añazco-Guenkova, A. M., Dietmann, S., López, J., Morón-Calvente, V., D’Ambrosi, S., Nombela, P., Zamacola, K., Mendizabal, I., Garcia‐Longarte, S., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01809-8 · Cited by 125
Circadian regulation of cancer cell and tumor microenvironment crosstalk
Xuan, W., Khan, F., James, C. D., Heimberger, A. B., Lesniak, M. S., & Chen, P. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.06.008 · Cited by 111
Qian, Y., Yin, Y., Zheng, X., Liu, Z., & Wang, X. (2024) · Biomarker Research · doi:10.1186/s40364-023-00549-7 · Cited by 131
“TMP195, a selective HDAC inhibitor, has been reported to reprogram TAMs into cells able to sustain a robust CD8 T cell-mediated anti-tumoral immune response, in an autochthonous mouse model of breast cancer and colorectal cancer [199, 200].”
Background
Metadata
- Authors
- Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., Davis, S. P., Lobera, M., Nolan, M. A., & Letai, A.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Nolan, Michael A.
- Letai, Anthony
- ORCID
- Venue
- Nature
- Published
- 2017-03
- Volume
- 543
- Issue
- 7645
- Pages
- 428-432
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8170529
- OpenAlex
- W2591627715
- Cited by
- 558
- References
- 35
- Citations by year
- 2026: 35 · 2025: 51 · 2024: 51 · 2023: 63 · 2022: 74 · 2021: 94 · 2020: 68 · 2019: 63 · 2018: 33 · 2017: 25
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA205967, F32CA180733)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- breast cancer, tumour-associated macrophages, antitumor immunity, tumor microenvironment, lung metastasis, chemotherapy synergy, T cell checkpoint blockade, CSF-1
- MeSH terms
- Animals, Benzamides, Breast Neoplasms, Cell Differentiation, Disease Models, Animal, Drug Synergism, Female, Humans, Lung Neoplasms, Macrophage Activation, Macrophages, Oxadiazoles, Phagocytosis, Cell Line, Tumor, Tumor Burden, Mice, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.